Research

Gartner named one of Popular Science’s “Brilliant 10” of 2015

Wed Sep 30, 2015

Zev Gartner, PhD

The next frontier in developing therapies for cancer and other diseases could come through studying organ development or tumor growth in living humans. Problem is, there’s no ethical way of doing that using current technology.

Zev Gartner, PhD, has focused on the next best thing: His lab is...

Ding applies stem cell method to recreate cells lost in spinal cord injuries

Thu Sep 17, 2015

Chris Goodfellow (Gladstone Institutes)

Sheng Ding, PhD

Sheng Ding, PhD, is a stem cell scientist who uses novel small molecules to control and reprogram stem cell activities in various tissue types. Applying his groundbreaking techniques, he has previously succeeded in transforming skin cells into functional brain, heart, liver, and insulin-producing...

Antibody Network partners with Celgene to develop cancer therapies

Tue Sep 15, 2015

Elisabeth Fall

James Wells, PhD

A new collaboration between Celgene Corp. and the Recombinant Antibody Network (RAN) will support the development of next-generation, antibody-based cancer therapies.

Bio-artificial Kidney Project Hoping to Raise Funds Through Social Media Crowdfunding Effort

Thu Sep 3, 2015

New Medical Technique Stacks Cells Like Legos

Wed Sep 2, 2015

‘Lego-stacking’ technique could help scientists grow human organs

Wed Sep 2, 2015

Roy receives JDRF funding to develop implants to treat type 1 diabetes

Tue Sep 1, 2015

Silicon nanopore membranes developed in the Roy Lab will provide material to encapsulate pancreatic islets.

UCSF School of Pharmacy faculty member Shuvo Roy, PhD, has received a three-year $1 million grant to create surgically implantable capsules of donor pancreas cells to free type 1 diabetes patients from daily insulin injections and the disease’s potentially life-threatening complications.

Virtual health care evaluated by UCSF and Stanford

Fri Aug 7, 2015

Student pharmacists at the UCSF School of Pharmacy and a student at the Stanford Graduate School of Business are teaming with a UCSF School of Pharmacy health economics professor to understand the rapidly evolving virtual health care world and how it is impacting the efficiency, effectiveness, and...

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Mon Jul 27, 2015

Deanna Kroetz, PhD

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can...

Study discovers why leading gout medication is ineffective for many

Tue Jul 14, 2015

Bobjgalindo

, CC BY-SA 3.0

, GFDL

Spiked rods of uric acid crystals from synovial fluid photographed under a microscope with polarized light. In patients with gout, such crystals can accumulate in the joints, causing pain and inflammation.

Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.

Categories: Research